Missing data in biologic oncology products

Journal of Biopharmaceutical Statistics

Volumn 19, Issue 6, 2009, Pages 1074-1084

  Rothmann, Mark D ^a   Koti, Kallappa ^a   Lee, Kyung Yul ^a   Lu, Hong Laura ^a   Shen, Yuan Li ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Disease free survival; Intent to treat principle; Loss to follow up; Overall survival; Progression free survival

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DATA ANALYSIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; LYMPHOMA; NONRESPONSE BIAS; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SENSITIVITY ANALYSIS; SOLID TUMOR; STATISTICAL SIGNIFICANCE;

BIOLOGICAL PRODUCTS; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; INTENTION TO TREAT ANALYSIS; NEOPLASMS;

EID: 75749126585     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400903242993     Document Type: Review

References (9)

1. Carroll, K. J. (2007). Analysis of progression-free survival in oncology trials: Some common statistical issues. Pharm. Stat. 6:99-113.
2. Dodd, L. E., Korn, E. L., Freidlin, B., Jaffe, C. C., Rubinstein, L. V., Dancey, J., Mooney, M. M. (2008). Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense? J. Clin. Oncol. 26:3791-3796.
3. European Medicines Agency. (2005). Guideline on the evaluation of anticancer medicinal products in man. www.emea.europa.eu/pdfs/human/ewp/ 020595en.pdf
4. European Medicines Agency. (2008). Methodological considerations for using Progression-Free Survival (PFS) as primary endpoint in confirmatory trials for registration. http://www.emea.europa.eu/pdfs/human/ewp/2799408en.pdf
5. Freidlin, B., Korn, E. L., Hunsberger, S., Gray, R., Saxman, S., Zujewski, J. A. (2007). Proposal for the use of progression-free survival in unblinded randomized trials. J. Clin. Oncol. 25:2122-2126.
6. Health Canada. (2007). Issues analysis summary: The use of progression-free survival as the efficacy endpoint for approval of targeted and chemotherapeutic agents for advanced cancer. http://www.hc-sc.gc.ca/dhp-mps/ prodpharma/activit/sci-com/ onco/sacot-ias-ccs-req-2007-08-eng.php
7. ICH E9 Expert Working Group. (1999). Statistical principles for clinical trials: ICH harmonized tripartite guideline. Stat. Med. 18:1905-1942.
8. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., Gwyther, S. G. (2000). New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92:205-216. (Pubitemid 30099779)
9. U.S. Food and Drug Administration. (2007). Guidance for industry: Clinical trial endpoints for the approval of cancer drugs and biologics. http://www.fda.gov/ cder/guidance/7478fnl.htm